Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 281

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

Open access
Kim, Cheolmin, Ryu, Dong-Kyun, Lee, Jihun, Kim, Young-Il, Seo, Ji-Min, Kim, Yeon-Gil, Jeong, Jae-Hee, Kim, Minsoo, Kim, Jong-In, Kim, Pankyeom, Bae, Jin Soo, Shim, Eun Yeong, Lee, Min Seob, Kim, Man Su, Noh, Hanmi, Park, Geun-Soo, Park, Jae Sang, Son, Dain, An, Yongjin, Lee, Jeong No, Kwon, Ki-Sung, Lee, Joo-Yeon, Lee, Hansaem, Yang, Jeong-Sun, Kim, Kyung-Chang, Kim, Sung Soon, Woo, Hye-Min, Kim, Jun-Won, Park, Man-Seong, Yu, Kwang-Min, Kim, Se-Mi, Kim, Eun-Ha, Park, Su-Jin, Jeong, Seong Tae, Yu, Chi Ho, Song, Youngjo, Gu, Se Hun, Oh, Hanseul, Koo, Bon-Sang, Hong, Jung Joo, Ryu, Choong-Min, Park, Wan Beom, Oh, Myoung-don, Choi, Young Ki, Lee, Soo-Young·2021·Nature Communications

Abstract

Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal antibodies (mAb) targeting the receptor binding domain (RBD) of the viral spike protein via antibody library constructed from peripheral blood mononuclear cells of a convalescent patient. The CT-P59 mAb potently neutralizes SARS-CoV-2 isolates including the D614G variant without antibody-dependent enhancement effect. Complex crystal structure of CT-P59 Fab/RBD shows that CT-P59 blocks interaction regions of RBD for angiotensin converting enzyme 2 (ACE2) receptor with an orientation that is notably different from previously reported RBD-targeting mAbs. Furthermore, therapeutic effects of CT-P59 are evaluated in three animal models (ferret, hamster, and rhesus monkey), demonstrating a substantial reduction in viral titer along with alleviation of clinical symptoms. Therefore, CT-P59 may be a promising therapeutic candidate for COVID-19.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-20602-5

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 281

Metadata

Authors
Kim, C., Ryu, D.-K., Lee, J., Kim, Y.-I., Seo, J.-M., Kim, Y.-G., Jeong, J.-H., Kim, M., Kim, J.-I., Kim, P., Bae, J. S., Shim, E. Y., Lee, M. S., Kim, M. S., Noh, H., Park, G.-S., Park, J. S., Son, D., An, Y., Lee, J. N., Kwon, K.-S., Lee, J.-Y., Lee, H., Yang, J.-S., Kim, K.-C., Kim, S. S., Woo, H.-M., Kim, J.-W., Park, M.-S., Yu, K.-M., Kim, S.-M., Kim, E.-H., Park, S.-J., Jeong, S. T., Yu, C. H., Song, Y., Gu, S. H., Oh, H., Koo, B.-S., Hong, J. J., Ryu, C.-M., Park, W. B., Oh, M.-D., Choi, Y. K., & Lee, S.-Y.
Venue
Nature Communications
Published
2021-01-12
Volume
12
Issue
1
Pages
288-288
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3119881634
Cited by
281
References
51
FWCI
19.10
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. https://app.cochat.ai/papers/10.1038/s41467-020-20602-5
The paper
Kim, C., Ryu, D.-K., Lee, J., Kim, Y.-I., Seo, J.-M., Kim, Y.-G., Jeong, J.-H., Kim, M., Kim, J.-I., Kim, P., Bae, J. S., Shim, E. Y., Lee, M. S., Kim, M. S., Noh, H., Park, G.-S., Park, J. S., Son, D., An, Y., . . . Lee, S.-Y. (2021). A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nature Communications. https://doi.org/10.1038/s41467-020-20602-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.